



華潤醫藥集團有限公司

China Resources Pharmaceutical Group Limited

(Incorporated in Hong Kong with limited liability)

(於香港註冊成立的有限公司)

(Stock Code: 3320)

(股份代號：3320)

24 December 2020

Dear Shareholders,

Letter to those shareholders who have elected to receive the corporate communications through the Company's website

We hereby notify you that the Circular dated 24 December 2020 in relation to the proposed acquisition of a controlling stake in Boya Bio-pharmaceutical Group of China Resources Pharmaceutical Group Limited (the "Company") in both English and Chinese are now available on the Company's website at <http://www.crpharm.com>.

Shareholders who have chosen to receive Corporate Communications ^{Note} by electronic means through the Company's website at <http://www.crpharm.com> in lieu of printed form and, for any reason have difficulty in receiving or gaining access to the above document, will upon request in writing to the Company's Share Registrar, Tricor Investor Services Limited, be promptly sent such document in printed form free of charge. Please kindly complete Part A of the attached Instruction Slip and return the completed Instruction Slip to the Company's Share Registrar by facsimile at (852) 2861 1465, by email at crpharm-3320@hk.tricorglobal.com or by post using the mailing label provided.

Please note that you may change your choice of means of receipt (whether by positive consent or by deemed consent) at any time, free of charge by completing Part B of the Instruction Slip and returning the completed Instruction Slip to the Company's Share Registrar using any of the above-mentioned methods. A copy of the Instruction Slip can also be obtained from the Company's Share Registrar.

Should you have any queries relating to this letter, please call our Share Registrar's investor services hotline at (852) 2980 1333 from 9:00 a.m. to 5:00 p.m., Monday to Friday (excluding public holidays).

Yours faithfully,
For and on behalf of
China Resources Pharmaceutical Group Limited
WANG Chuncheng
Chairman

Encl.

Note: Corporate Communications refer to any document issued or to be issued by the Company for information or action of holders of securities of the Company, including but not limited to annual report, summary financial report (where applicable), interim report, summary interim report (where applicable), notice of meeting, listing document, circular and proxy form.

敬啟者：

致已選擇以本公司的網站收取公司通訊之股東

吾等現謹通知閣下，華潤醫藥集團有限公司（「本公司」）日期為二零二零年十二月二十四日之通函，乃有關建議收購博雅生物製藥集團控股權的英文本及中文本，現已登載於本公司的網站<http://www.crpharm.com>。

已選擇透過本公司的網站(<http://www.crpharm.com>)以電子方式瀏覽公司通訊^註以取代收取印刷本的股東，如因任何理由以致收取或接收上述文件上出現困難，只要向本公司股份過戶登記處卓佳證券登記有限公司提出書面要求，均可立即獲免費發送該文件的印刷本。請閣下填妥隨附指示回條甲部，並將已填妥之指示回條傳真至(852) 2861 1465、電郵至crpharm-3320@hk.tricorglobal.com或利用郵寄標籤寄回本公司股份過戶登記處。

請注意 閣下可以隨時透過填寫指示回條乙部更改已選擇的收取方式（不論是正面同意或是被視為同意的情况），費用全免。填妥的指示回條須透過上述任何一種方式交回本公司股份過戶登記處。股東亦可向本公司股份過戶登記處索取該指示回條。

倘閣下對本函件有任何疑問，請於星期一至星期五（公眾假期除外）上午9時至下午5時致電本公司股份過戶登記處的投資者服務熱線(852)2980 1333。

此 致

列位股東 台照

代表
華潤醫藥集團有限公司
王春城
主席
謹啟

二零二零年十二月二十四日

附件

註： 公司通訊指由本公司發出或將予發出以供本公司證券持有人參照或採取行動的任何文件，其中包括但不限於年報、財務摘要報告（如適用）、中期報告、中期摘要報告（如適用）、會議通告、上市文件、通函及代表委任表格。

INSTRUCTION SLIP 指示回條



華潤醫藥集團有限公司

China Resources Pharmaceutical Group Limited

(Incorporated in Hong Kong with limited liability)

(於香港註冊成立的有限公司)

(Stock Code: 3320)

(股份代號：3320)

Please complete, sign and return this instruction slip to the Share Registrar of China Resources Pharmaceutical Group Limited (the "Company"), Tricor Investor Services Limited, by facsimile at (852) 2861 1465, by email at crpharm-3320@hk.tricorglobal.com or by post using the mailing label provided.

請填妥及簽署下列指示回條，並傳真至(852) 2861 1465、電郵至crpharm-3320@hk.tricorglobal.com或利用郵寄標籤寄回華潤醫藥集團有限公司(「本公司」)股份過戶登記處卓佳證券登記有限公司。

Part A – To receive a printed version of the Circular dated 24 December 2020 in relation to the proposed acquisition of a controlling stake in Boya Bio-pharmaceutical Group (the "Enclosed Document"):
甲部 – 收取日期為二零二零年十二月二十四日之通函，乃有關建議收購博雅生物製藥集團控股權(「隨附文件」)之印刷本：

I/We have chosen to receive the Enclosed Document by electronic means through the Company's website but would like to receive them in printed form.
本人/吾等已選擇透過本公司的公司網站以電子方式瀏覽隨附文件，但希望收取其印刷本。

Part B – To elect/change the means of receipt of future Corporate Communications:
乙部 – 選擇/更改日後收取公司通訊之形式：

I/We would like to receive all future Corporate Communications* of the Company:
關於本公司日後發佈的所有公司通訊*，本人/吾等欲：

(Please tick only one box) (只可選擇一項，請於以下適當的空格加上「✓」號)

- in printed form; or
只收取印刷本；或
- by electronic means in lieu of printed form.
以電子方式取代印刷本。

My/Our email address:
本人/吾等的電郵地址：

(Please ensure your email address is properly filled in for the purpose of receiving the notification of release of Corporate Communications)
(請確保填上正確的電郵地址以作收取公司通訊發佈的通知之用)

Name(s) of Shareholder(s) in English (Please use **BLOCK LETTERS**)
股東的英文名稱(請以大楷書寫)

Name(s) of Shareholder(s) in Chinese
股東的中文名稱

Registered Address of Shareholder(s)
股東的登記地址

Contact Telephone Number
聯絡電話

Signature(s)
簽署

Date
日期

- Notes:**
- The above instruction will apply to all Corporate Communications to be sent to you until you inform us otherwise.
 - If any shares are held in joint names, all joint holders OR the joint holder whose name stands first on the register of members of the Company should sign this form in order for it to be valid.
 - This instruction slip with no box ticked, with more than one box ticked, or otherwise incorrectly completed will be voided at the discretion of the Company.
 - Printed versions of all future Corporate Communications of the Company will be available on request in writing to the Share Registrar of the Company. Such Corporate Communications will also be available on the website at <http://www.crpharm.com>

* Corporate Communications refers to any document issued or to be issued by the Company for information or action of holders of securities of the Company, including but not limited to annual report, summary financial report (where applicable), interim report, summary interim report (where applicable), notice of meeting, listing document, circular and proxy form.

- 註：**
- 上述指示將適用於本公司將會發送給閣下的所有公司通訊文件，直至閣下另行通知為止。
 - 如任何股份以聯名方式持有，則所有聯名持有人或名列本公司股東名冊的首名聯名持有人須於本表格上簽署，方為有效。
 - 如未有在任何上述適當空格加上「✓」號，或在超過一個空格加上「✓」號，或在其他方面填寫不正確，本公司可酌情決定將本指示回條作廢。
 - 本公司日後所有公司通訊的印刷本，可透過書面通知向本公司股份過戶登記處索取。該等公司通訊文件亦登載於網站(<http://www.crpharm.com>)。

* 公司通訊指由本公司發出或將予發出以供本公司證券持有人參照或採取行動的任何文件，其中包括但不限於年報、財務摘要報告(如適用)、中期報告、中期摘要報告(如適用)、會議通告、上市文件、通函及代表委任表格。



Mailing Label 郵寄標籤

Please cut the mailing label and stick this on an envelope to return the Request Form to us.
No postage stamp is required for local mailing

當閣下寄回此表格時，請將此郵寄標籤剪貼於信封上。
如在本港投寄，閣下無需支付郵費或貼上郵票

Tricor Investor Services Limited
卓佳證券登記有限公司
Freeport No. 簡便回郵號碼：37
Hong Kong 香港